<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122729">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01953172</url>
  </required_header>
  <id_info>
    <org_study_id>FDS-NBU-1034</org_study_id>
    <nct_id>NCT01953172</nct_id>
  </id_info>
  <brief_title>Health Status and Quality of Life in the Elderly</brief_title>
  <official_title>Exploratory, Double-blind, Randomized, Placebo Controlled Study of AMP-886 in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unilever R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sprim Advanced Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unilever R&amp;D</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to investigate the effect of AMP886 (alpha-tocotrienol) on health
      status and quality of life measures, cognitive functioning, oxidative stress, inflammation
      markers and other symptoms effects on skin, sleep and vision in the elderly.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Effects on health status and quality of life</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective of this exploratory study is to evaluate the effects of AMP886 on health status</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects on health status and quality of life</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective of this exploratory study is to evaluate the effects of AMP886 on quality of life measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects on health status and quality of life</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective of this exploratory study is to evaluate the effects of AMP886 on cognitive functioning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects on health status and quality of life</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective of this exploratory study is to evaluate the effects of AMP886 on  oxidative stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects on health status and quality of life</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective of this exploratory study is to evaluate the effects of AMP886 on  inflammation markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects on health status and quality of life</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective of this exploratory study is to evaluate the effects of AMP886 on  skin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects on health status and quality of life</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective of this exploratory study is to evaluate the effects of AMP886 on  vision</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMP-886 (alpha-tocotrienol) in capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMP-886 (alpha-tocotrienol) in capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AMP-886</intervention_name>
    <description>AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules</description>
    <arm_group_label>AMP-886 (alpha-tocotrienol) in capsules</arm_group_label>
    <other_name>alpha-tocotrienol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 65-85 years old

          -  ECOG Performance score 0 to 1

          -  Body mass index 22-30 kg/m2

          -  Body weight &gt;60 kg

          -  Habit to consume standard breakfast like toast, bread, butter/margarine, eggs, bacon,
             cereals with milk

          -  Comply with protocol and likely to be compliant with prescribed product

        Exclusion Criteria:

          -  Renal insufficiency or failure at screening

          -  Current or previous positive documented history of any chronic inflammatory state
             including chronic infection, arthritis, or collagen vascular disorder.

          -  Comorbid medical conditions

          -  Use of prescription medication for chronic conditions

          -  Use of hormone replacement therapy (with the exception of levothyroxine)

          -  Uncontrolled hypertension

          -  Use of hemostatic agents

          -  Hemorrhagic disorder and/or coagulation disorder

          -  Clinically important bleeding within 90 days prior to screening visit

          -  Fat malabsorption syndromes

          -  Constipation and/or abdominal pain/discomfort that require dietary supplements or
             medical therapy

          -  History of smoking within 1 year prior to visit 1.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C Verhoeven, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Unilever Research and Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>C Verhoeven, PhD</last_name>
    <phone>+31 10 4605441</phone>
    <email>carole.verhoeven@unilever.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>S Jackson, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Whipps Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>A Bewley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Manchester Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>J Lear, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>November 25, 2013</lastchanged_date>
  <firstreceived_date>September 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tocotrienol, alpha</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
